National Assessment of Prostate and Colon Cancer Screening Using National Health Interview Survey (NHIS)
Moderator
Aunovro H Sen, Other, Rutgers Preparatory School, Belle Mead, NJ, United States
Speakers
Ansh Kulkarni; Sohah Kulkarni, Other, Princeton Day School, Princeton, NJ, United States; Rajesh Balkrishnan, PhD
OBJECTIVES: Prostate and colon cancers remain the most prevalent cancers in the United States. In 2024, prostate cancer was the leading cause of newly diagnosed cancers in male whereas colon cancer was ranked three for both male and female. This study assessed the national screening rates for prostate and colon cancer including their demographic characteristics.
METHODS: National health interview survey (NHIS) data from 2019, 2021, and 2023 was used to assess national screening rates for prostate and colon cancer. NHIS collects information about the health of the US population including prevalence of diseases, health behaviors, access to healthcare services and health insurance coverage. We utilized an annual Cancer Control Supplement (CCS) which collects information on practices of cancer-related health behaviors including cancer screening. Descriptive statistics including proportions were used to report the screening rates and associated characteristics.
RESULTS: A total of 26,395 sample adults with cancer screening were included in the assessment. Rates of prostate cancer across three assessment years 2019, 2021, and 2023 were 49.23%, 47.35% and 47.92%, respectively. Similarly, the rate of colon cancer across three assessment years 2019, 2021, and 2023 were 60.11%, 59.75% and 62.0%, respectively. On average rate of screening for prostate (10.6%) and colon cancer (10.9%) were consistently lower in black adults across all the year as compared to their national representation as per census bureau. Among the screened adults Insurance coverage was significantly higher, majority of the screened adults were from small to large metropolitan areas and were college graduates.
CONCLUSIONS: While rates of both prostate and colon cancer remain stables across all the assessment years, there are demographic differences among screened adults in the United States with black adults consistently having lower rates of cancer screening. Additionally, access to health insurance could be strong driver to access screening services.
METHODS: National health interview survey (NHIS) data from 2019, 2021, and 2023 was used to assess national screening rates for prostate and colon cancer. NHIS collects information about the health of the US population including prevalence of diseases, health behaviors, access to healthcare services and health insurance coverage. We utilized an annual Cancer Control Supplement (CCS) which collects information on practices of cancer-related health behaviors including cancer screening. Descriptive statistics including proportions were used to report the screening rates and associated characteristics.
RESULTS: A total of 26,395 sample adults with cancer screening were included in the assessment. Rates of prostate cancer across three assessment years 2019, 2021, and 2023 were 49.23%, 47.35% and 47.92%, respectively. Similarly, the rate of colon cancer across three assessment years 2019, 2021, and 2023 were 60.11%, 59.75% and 62.0%, respectively. On average rate of screening for prostate (10.6%) and colon cancer (10.9%) were consistently lower in black adults across all the year as compared to their national representation as per census bureau. Among the screened adults Insurance coverage was significantly higher, majority of the screened adults were from small to large metropolitan areas and were college graduates.
CONCLUSIONS: While rates of both prostate and colon cancer remain stables across all the assessment years, there are demographic differences among screened adults in the United States with black adults consistently having lower rates of cancer screening. Additionally, access to health insurance could be strong driver to access screening services.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD29
Topic
Health Service Delivery & Process of Care
Disease
SDC: Oncology